載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$3.82
−US$0.05 · -1.29%
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
前收盤價
US$3.82
−US$0.05 · -1.29%
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
85
深度低估
情緒
57
多空交錯
風險
46
風險偏高
動能
74
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
日內區間
目前US$3.82
52週區間
目前US$3.82
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.96億 USD | 3.51億 USD | 4.43億 USD | 4.11億 USD | 4.14億 USD |
| 銷貨成本 | — | 755.2萬 USD | 614.8萬 USD | 141.8萬 USD | 7040.5萬 USD |
| 毛利 | 2.96億 USD | 3.44億 USD | 4.37億 USD | 4.09億 USD | 3.43億 USD |
| 研究與開發 | 9513.6萬 USD | 1.11億 USD | 1.16億 USD | 4426.5萬 USD | 7040.5萬 USD |
| 銷售、一般及管理費用 | 8225.6萬 USD | — | — | 1.16億 USD | — |
| 營業費用 | 1.77億 USD | 2.51億 USD | 13.82億 USD | 1.59億 USD | 1.11億 USD |
| 利息收入 | 407.6萬 USD | 446.8萬 USD | 1897.1萬 USD | 950.1萬 USD | 72.6萬 USD |
| 利息支出 | 3274.6萬 USD | 3303.4萬 USD | 2162.9萬 USD | 759.8萬 USD | 3115萬 USD |
| 折舊和攤銷 | 188.1萬 USD | 201.1萬 USD | 157.5萬 USD | 141.8萬 USD | 150萬 USD |
| 營業利益 | 1.19億 USD | 9312.4萬 USD | −9.45億 USD | 2.5億 USD | 2.32億 USD |
| 淨利 | 2401.7萬 USD | 88萬 USD | −10.02億 USD | 1.75億 USD | 5.28億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.68
上漲空間 74.87%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年4月2日 | 597:500 | — | — |
已生效 2019年4月2日
597:500
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2032.13萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1673.47萬0.02%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1302.54萬0.13%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF720.06萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO557.81萬0.04%139.17億 USD0.24%US$356.78+0.94%
Pacer US Small Cap Cash Cows ETFCALF502.74萬0.14%35.87億 USD0.59%US$54.66-0.16%
iShares Biotechnology ETFIBB483.86萬0.05%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS452.61萬0.01%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOPacer US Small Cap Cash Cows ETFCALFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
